DeCure for Thrombophilia, X-linked, due to factor 9 defect
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for thrombophilia, X-linked, due to factor 9 defect — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleThrombophilia, X-linked, due to factor 9 defect maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for thrombophilia, x-linked, due to factor 9 defect is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
The Journal of Maternal-Fetal & Neonatal Medicine · 2015 · 12 citations
The investigation of hereditary and acquired thrombophilia risk factors in the development of complications in pregnancy in Croatian women
AbstractOBJECTIVES: To investigate the genetic and acquired thrombophilic risk factors in pregnancy-associated complications and venous thromboembolism (VTE) and evaluate the association between particular thrombophilic risk factors and thromboembolic complications. METHODS: In this study, pregnant women with pregnancy complications and VTE (N = 101) were the study group, and the control group were women with normal pregnancy (N = 102). All women underwent testing for factor V Leiden mutation (FVL), mutation of the coagulation factors II (FII20210), methylenetetrahydrofolate reductase (MTHFR), plasminogen activator inhibitor-1, antithrombin III (ATIII), protein C (PC) and protein S, lupus anticoagulant (LAC) antibodies, anticardiolipin antibodies and anti-beta-2-glycoprotein-1. RESULTS: In this study group, mutations of the FVL was 15.8% (16/101), FII20210 5.9% (6/101) and the MTHFR at locus 677 was TT in 19.8% (20/101). Deficiency of ATIII and PC were rare: 3.0% and 1.0%, respectively. LAC were significantly higher in the study group than in the control group: 32.7% versus 3.9%; p < 0.0005. Pregnant women with VTE have been more frequent for FVL (41.7%; p < 0.005), PC deficiency (25.0%; p < 0.005) and LAC (33.3%; p < 0.005). Combination of FVL and MTHFR mutation was related to the risk of recurrent fetal death and habitual abortion. CONCLUSION: The inherited and the acquired thrombophilic risk factors were found to be up to 10 times more common in the study group than in the control group.
AbstractBACKGROUND: The Flow Redirection Endoluminal Device (FRED) is a dual-layer flow diverting stent with a dense inner mesh and outer braided support providing superior deployment control. Covalently bonded Poly(2-methoxyethyl acrylate) X coating was introduced to decrease metal-induced thrombogenicity in the newer FRED X variant. The objective of the current study is to evaluate procedural thromboembolic events associated with both variants. METHODS: A single-center retrospective analysis was undertaken comparing angiographically detected intraprocedural thromboembolic events, postprocedural magnetic resonance diffusion weighted imaging lesions (MR-DWI+), as well as a composite combined endpoint. Periprocedural (<24 hours) clinical events, demographics, aneurysm characteristics and platelet aggregation (using P2Y12 reactivity unit, PRU) were analyzed. RESULTS: Treatment was performed with 19 FRED procedures in 18 patients with 19 aneurysms, and with 37 FRED X procedures in 35 patients harboring 40 aneurysms. Both groups achieved therapeutic preprocedural platelet inhibition by PRU testing. Intraprocedural thromboembolic events including intraluminal filling defects and side-branch slowing or loss occurred in 7/19 (36.8%) FRED and 0/37 FRED X procedures (P = 0.0002), with all being successfully recanalized using intra-arterial platelet inhibitors, without symptomatic ischemic or hemorrhagic events. The composite endpoint was reached in 11/19 (57.9%) FRED and 5/37 (13.5%) FRED X cases (P = 0.001), with multivariable analysis identifying device type (P = 0.015) among age, gender, and PRU. CONCLUSIONS: The surface modification of the FRED X device may be associated with improved thrombogenic risk profile in our cohort, with elimination of intraprocedural thrombus formation and reduction of composite thromboembolic events.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
